Memantine neurology data

Researchers from Kings College London and colleagues reported that memantine was ineffective in treating cognitive impairment and dementia in patients with Down syndrome in the double-blind, U.K. and Norwegian MEADOWS trial in 173 patients aged>=40 years old. Relative to placebo, memantine led to non-significantly greater mean changes from baseline to week 52 of 4.1, 8.5 and 2 points for DAMES, ABS part I and ABS part II scores, respectively (p=0.36, p=0.15 and p=0.67). The scales measure cognition and function. ...